Mara Maia

Dr. Mara Maia


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
NONatasha de Oliveira
Natasha de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
VSVitória Adrielly Catschor dos Santos
Vitória Adrielly Catschor dos Santos
MMMara Maia
Mara Maia
TThaís Oliveira
Thaís Oliveira
ODOdir Dellagostin
Odir Dellagostin
The first leptospiral recombinant vaccine was developed in the late 1990s. Since then, progress in the fields of reverse vaccinology (RV) and structural vaccinology (SV) has significantly improved the identification of novel surface-exposed and conserved vaccine targets. However, developing recombinant vaccines for leptospirosis faces various challenges, including selecting the ideal expression platform or delivery system, assessing immunogenicity, selecting adjuvants, establishing vaccine formulation, demonstrating protective efficacy against lethal disease in homologous challenge, achieving full renal clearance using experimental models, and reproducibility of protective efficacy against heterologous challenge. In this review, we highlight the role of the expression/delivery system employed in studies based on the well-known LipL32 and leptospiral immunoglobulin-like (Lig) proteins, as well as the choice of adjuvants, as key factors to achieving the best vaccine performance in terms of protective efficacy against lethal infection and induction of sterile immunity.

22 July 2024 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
RTRafael Carracena de Souza Tapajóz
Rafael Carracena de Souza Tapajóz
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
NONatasha de Oliveira
Natasha de Oliveira
MMMara Maia
Mara Maia
ANAmilton Clair Pinto Seixas Neto
Amilton Clair Pinto Seixas Neto
ODOdir Dellagostin
Odir Dellagostin
Leptospirosis, a neglected zoonotic disease, is caused by pathogenic spirochetes belonging to the genus Leptospira and has one of the highest morbidity and mortality rates worldwide. Vaccination stands out as one of the most effective preventive measures for susceptible populations. Within the outer membrane of Leptospira spp., we find the LIC12287, LIC11711, and LIC13259 lipoproteins. These are of interest due to their surface location and potential immunogenicity. Thorough examination revealed the conservation of these proteins among pathogenic Leptospira spp.; we mapped the distribution of T- and B-cell epitopes along their sequences and assessed the 3D structures of each protein. This information aided in selecting immunodominant regions for the development of a chimeric protein. Through gene synthesis, we successfully constructed a chimeric protein, which was subsequently expressed, purified, and characterized. Hamsters were immunized with the chimeric lipoprotein, formulated with adjuvants aluminum hydroxide, EMULSIGEN®-D, Sigma Adjuvant System®, and Montanide™ ISA206VG. Another group was vaccinated with an inactivated Escherichia coli bacterin expressing the chimeric protein. Following vaccination, hamsters were challenged with a virulent L. interrogans strain. Our evaluation of the humoral immune response revealed the production of IgG antibodies, detectable 28 days after the second dose, in contrast to pre-immune samples and control groups. This demonstrates the potential of the chimeric protein to elicit a robust humoral immune response; however, no protection against challenge was achieved. While this study provides valuable insights into the subject, further research is warranted to identify protective antigens that could be utilized in the development of a leptospirosis vaccine. Key points: • Several T- and B-cell epitopes were identified in all the three proteins. • Four different adjuvants were used in vaccine formulations. • Immunization stimulated significant levels of IgG2/3 in vaccinated animals.

4 October 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
TBTiffany Thurow Bunde
Tiffany Thurow Bunde
NONatasha Rodrigues de Oliveira
Natasha Rodrigues de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
APAna Carolina Kurz Pedra
Ana Carolina Kurz Pedra
MMMara Maia
Mara Maia
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN

1 July 2021 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
MSMariangela Freitas da da Silveira
Mariangela Freitas da da Silveira
MMMarilia A Mesenburg
Marilia A Mesenburg
ODOdir Dellagostin
Odir Dellagostin
NONatasha de Oliveira
Natasha de Oliveira
MMMara Maia
Mara Maia
BHBernardo L Horta
Bernardo L Horta
Large-scale epidemiological studies of seroprevalence of antibodies against SARS-CoV-2 often rely on point-of-care tests that provide immediate results to participants. Yet, little is known on how long rapid tests remain positive after the COVID-19 episode, or how much variability exists across different brands and even among batches of the same test. In November 2020, we assessed the sensitivity of three tests applied to 133 individuals with a previous positive PCR result between April and October. All subjects provided finger prick blood samples for two batches (A and B) of the Wondfo lateral-flow IgG/IgM test, and dried blood spot samples for the S-UFRJ ELISA test. Overall sensitivity levels were 92.5% (95% CI 86.6–96.3), 63.2% (95% CI 54.4–71.4) and 33.8% (95% CI 25.9–42.5) for the S-UFRJ test, Wondfo A and Wondfo B tests, respectively. There was no evidence of a decline in the positivity of S-UFRJ with time since the diagnosis, but the two Wondfo batches showed sharp reductions to as low as 41.9% and 19.4%, respectively, for subjects with a positive PCR in June or earlier. Positive results for batch B of the rapid test were 35% to 54% lower than for batch A at any given month of diagnosis. Whereas the ELISA test showed high sensitivity and stability of results over the five months of the study, both batches of the rapid test showed substantial declines, with one of the batches consistently showing lower sensitivity levels than the other. ELISA tests based on dried-blood spots are an inexpensive alternative to rapid lateral-flow tests in large-scale epidemiological studies. The study was funded by the “Todos Pela Saúde” initiative, Instituto Serrapilheira, Brazilian Ministry of Health, Brazilian Collective Health Association (ABRASCO) and the JBS S.A. initiative ‘Fazer o Bem Faz Bem’.

1 January 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
MSMariangela Freitas da da Silveira
Mariangela Freitas da da Silveira
MMMarilia Mesenburg
Marilia Mesenburg
ODOdir Dellagostin
Odir Dellagostin
NONatasha de Oliveira
Natasha de Oliveira
MMMara Maia
Mara Maia
CVCesar G. Victora
Cesar G. Victora
Background: Large-scale epidemiological studies of seroprevalence of antibodies against SARS-CoV-2 often rely on point-of-care tests that provide immediate results to participants. Yet, little is known on how long rapid tests remain positive after the COVID-19 episode, or how much variability exists across different brands and even among batches of the same test. Methods: In November 2020, we assessed the sensitivity of three tests applied to 133 individuals with a previous positive PCR result between April and October. All subjects provided finger prick blood samples for two batches (A and B) of the Wondfo lateral-flow IgG/IgM test, and dried blood spot samples for the S-UFRJ ELISA test. Results: Overall sensitivity levels were 92.5% (95% CI 86.6;96.3), 63.2% (54.4;71.4) and 33.8% (25.9;42.5) for the S-UFRJ test, Wondfo A and Wondfo B tests. There was no evidence of a decline in the positivity of S-UFRJ with time since the diagnosis, but the two Wondfo batches showed sharp reductions to as low as 41.9% and 19.4%, respectively, for subjects with a positive PCR in June or earlier. Positive results for batch B of the rapid test were 35% to 54% lower than for batch A at any given month of diagnosis. Interpretation: Whereas the ELISA test showed high sensitivity and stability of results over the five months of the study, both batches of the rapid test showed substantial declines, with one of the batches consistently showing lower sensitivity levels than the other. ELISA tests based on dried-blood spots are an inexpensive alternative to rapid lateral-flow tests in large-scale epidemiological studies. Funding: The study was funded by the “Todos Pela Saúde” initiative, Instituto Serrapilheira, Brazilian Ministry of Health, Brazilian Collective Health Association (ABRASCO) and the JBS S.A. initiative ‘Fazer o Bem Faz Bem’. Declaration of Interests: None to Declare Ethics Approval Statement: Ethical approval by the Brazilian National Ethics Committee (process number 30415520.2.0000.5313).

25 April 2023 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
LCLaura Junqueira de Camargo
Laura Junqueira de Camargo
MMMara Maia
Mara Maia
RWRafael dos Santos Woloski
Rafael dos Santos Woloski
CRCaroline Rizzi
Caroline Rizzi
GMGustavo Marçal Schmidt Garcia Moreira
Gustavo Marçal Schmidt Garcia Moreira
LPLuciano da Silva Pinto
Luciano da Silva Pinto